Search

everythinglearnresearchcommunity

for

Search:↓

Diagnosing and treating skin conditions is challenging, especially when drug reactions mimic other diseases.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

CD2 might be a new treatment target for patchy alopecia areata.

Old drugs can be used for new treatments, saving time and money, but there are challenges like needing more evidence and legal concerns.

The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Alopecia is linked to various health and mental conditions, impacts life quality, and needs medical attention beyond its cosmetic effects.

Mesenchymal stem cell therapy may help treat alopecia areata by promoting hair growth and reducing inflammation.

Some plants used in traditional medicine may help treat cancer because they contain proteins that can inactivate ribosomes.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Methotrexate is a promising and safe treatment for severe alopecia areata, with better results when combined with corticosteroids.

Biologics show promise in treating various stubborn skin diseases, but more research and better reimbursement criteria are needed.

Alopecia areata patients, especially women with nail issues or atopic diseases, are at higher risk for other autoimmune diseases.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.

The conference presented findings on how vitamin D levels, genetic factors, and lifestyle choices like smoking and yoga affect various health conditions and diseases.

Kids with alopecia areata had lower vitamin D levels than healthy kids.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Type 1 diabetes patients often have other autoimmune diseases, which complicate their care.

Severe anti-TNF-α induced scalp eruptions often need stopping the drug and using systemic therapy to avoid scarring.

Most skin rashes in rheumatoid arthritis patients were not caused by their medication, and careful evaluation allowed most to keep taking their beneficial treatment.

New treatments for skin conditions in children include a preferred drug for birthmark reduction, proactive creams for eczema and vitiligo, a safe psoriasis medication, and special tissues and socks for eczema and fungal infections.

A patient lost all their hair while on rheumatoid arthritis medication.

The symposium highlighted the importance of understanding disease mechanisms for targeted dermatology treatments.

Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.